Study: NCT02864368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day TMZ
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day TMZ
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day TMZ
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21-day TMZ
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21-day TMZ
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component A
Description: 500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component A
Description: 500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component A
Description: 500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component A
Description: 500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component A
Description: 500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria booster
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria booster
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria booster
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria booster
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria booster
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Pre-Conditioning
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Pre-Conditioning
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Pre-Conditioning
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Pre-Conditioning
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Pre-Conditioning
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component B
Description: 500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component B
Description: 500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component B
Description: 500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered